Dutch payers are pragmatic, especially when discussing medical devices, isn’t it, Ron de Graff?
The market access process in the Netherlands can be very special, especially for medical devices. Besides standard reimbursement processes with [...]
Podcast Q&A: FDA Guidance Documents: Shaping the Future of RWD Curation and RWE Innovation
This podcast segment features the Q&A from IQVIA's May 25, 2022 webinar hosted IQVIA experts Raina Olexa, Senior Principal Scientist [...]
The Belgium reimbursement pathway for digital health applications is similarly easy as in Germany, correct Katrien de Groote?
Belgium has created a similar fast-track process as in Germany even though that some differences exist. Anyway, core question with [...]
Unlocking the Value of Real-World Data to Provide Real-World Care
For this tHEORetically speaking video interview, we spoke with Mary Tran, MS, from Syapse for a deep dive into the [...]
Boston Strategic Partners Supplier Spotlight
Supplier Spotlight® highlights the unique skills and services offered by organizations who are part of our CONNECTED COMMUNITY™. We recently [...]
Is European market access really so difficult? Tell us the truth about being successful in Europe, Esther Nzenza!
Europe is one continent, with one Union (plus the UK)… Health policy is still the responsibility of each individual country [...]
HealthLumen Supplier Spotlight
HealthLumen's mission is to improve global health outcomes by creating data-driven insights for decision making. We are specialists in quantifying the burden of chronic diseases into the future.
Trends and challenges in the Value, Evidence, and Access landscape: an interview with David Sykes, Head of VEA, Fishawack Health
For this installment of tHEORetically speaking, David Sykes sat down with HealthEconomics.com to provide an overview of Fishawack [...]
What can Europeans learn from Canada for the upcoming EU joint HTA, Gabriel Tremblay?
EU joint HTA will become reality in the next few years as communicated recently by the European Commission. However, applicability [...]
Differentiate Your Product From the Competition: Give Healthcare Decision Makers the Information They Need
In this competitive pharmaceutical market access landscape, payers are preparing budgets and financial forecasts well ahead of product launches, [...]
Podcast Q&A: Cracking the Code: When and How to Validate ICD Algorithms for RWE
This podcast segment features the Q&A from PHAR LLC's webinar from April 12, 2022 which featured experts from PHAR, Genentech, [...]
Podcast Q&A: Optimizing Real-World Evidence for Maternal and Neonatal Outcomes
This podcast segment features the Q&A from HealthCore's webinar from April 9, 2022 which featured an expert panel of health [...]
Digital Health Care is already fully utilized in the US, isn’t it?
Dr. Stefan Walzer and Kate Claessens, the experienced consultant on healthcare in the US, are discussing the public acceptance as well as the various reimbursement pathways in [...]
Foundation of Sand
The last decade has seen an explosion of interest in and production of real world evidence (RWE). But I’m afraid there is a day of reckoning approaching.
MArS Supplier Spotlight
Supplier Spotlight® highlights the unique skill sets and service offerings from organizations who are part of our CONNECTED COMMUNITY™. Below [...]
A Farewell Message from Patti Peeples, HealthEconomics.Com Founder
On March 31, I’ll be retiring from HealthEconomics.Com and our parent company, Scientist.com. I’m passing the mantle onto an exceptional team at Scientist.com, and HealthEconomics.Com will be supported by a larger staff and even more resources.
Does the Italian reimbursement pathway allow for innovative drugs being highly priced, Dr. Stefano Capri and Dr. Entela Xoxi?
The Italian reimbursement system is unique in terms of its structure, especially also for innovative drugs. However, what does the new innovation pathway means to the [...]
GPI Supplier Spotlight
Find out more about Global Pricing Innovations (GPI) whose vison and goal is to support industry and payers in achieving a sustainable balance between pricing and patient access.
Delivering Real World Data-Driven Insights: An Executive Interview with Wendy Shusko and Jason Drenning
Delivering Real World Data-Driven Insights:An Executive Interview with Wendy Shusko and Jason Drenning Wendy Shusko, President and CEO and Jason [...]
Podcast Q&A: How Literature Review Automation and Efficient Processes Streamline RWE HEOR Studies?
This podcast segment features the Q&A from Evidence Partners' webinar from March 9, 2022. This webinar, moderated by Dr. Patti [...]
10 Creative Ways to Make Your Webinar More Engaging
Written by Scientist.com Marketing Services Following the pandemic, the world has had to adapt to a new way of life in an [...]
What are the specific elements about the Austrian market access pathway, Dr. Anna Bucsics?
The Austrian market access pathway in the outpatient setting is unique in its pragmatic approach with their box system. The [...]
The private health insurances as the entrance into German market access – is this true, Dr. Bastian Biermann?
The German health care system consists of the statutory and private health insurances, whereas the latter covers around 10% of [...]
How can a company derive the optimal price for their medical product, Dr. Renato, Dellamano?
What are drivers of pricing and ultimately negotiations? How can a global strategy best be implemented in individual countries? How [...]
How do innovations reach patients in German hospitals, Dr. Sebastian Casu?
How important are the famous NUBs, OPS and DRG values? How can innovations reach patients beyond administrative barriers? What are [...]
